Persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide treated with milrinone: A case report

Turkish Journal of Pediatrics

Volumn 52, Issue 1, 2010, Pages 78-80

  Tzialla, Chryssoula ^a   Cerbo, Rosa Maria ^a   Perotti, Gianfranco ^a   Stronati, Mauro ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Milrinone; Newborn; Phosphodiesterase III inhibitor; Pulmonary hypertension

Indexed keywords

ADRENALIN; AMPICILLIN; C REACTIVE PROTEIN; CEFTAZIDIME; DOPAMINE; GENTAMICIN; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHORUS; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC THERAPY; ARTERIAL OXYGEN SATURATION; ARTICLE; ARTIFICIAL VENTILATION; BIRTH; BLOOD CARBON DIOXIDE TENSION; BLOOD OXYGEN TENSION; BLOOD PRESSURE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG RESPONSE; DUCTUS ARTERIOSUS; ECHOCARDIOGRAPHY; FEVER; HEART RATE; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; MONOTHERAPY; NEUTROPENIA; NEWBORN; OXYGENATION; OXYGENATION INDEX; PATENT FORAMEN OVALE; PERSISTENT PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; TRICUSPID VALVE;

HUMANS; INFANT, NEWBORN; MILRINONE; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; PHOSPHODIESTERASE INHIBITORS; TREATMENT FAILURE;

EID: 77950443103     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005; 39: 492-503.
2. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2003; 36: 529-535.
3. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98: 706-713.
4. Heal CA, Spencer SA. Methaemoglobinaemia with high-dose nitric oxide administration. Acta Paediatr 1995; 84: 1318-1319.
5. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM. Role for endothelin-1 induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001; 89: 357-364.
6. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993; 265: L555-564.
7. Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterese-3 inhibitors. Chest 2004; 125: 644-651.
8. Thelitz S, Oishi P, Sanchez LS, et al. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. Paediatr Crit Care Med 2004; 5: 234-239.
9. Deb B, Bradford K, Pearl R. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28: 795-799.
10. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107: 996-1002.
11. Bassler D, Choong K, McNamara PJ, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89: 1-5.
12. McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Critical Care 2006; 21: 217-222.